Collaboration has culminated in meaningful, lasting changes for the benefit of stakeholders in the electronic collection of clinical outcome assessment data in clinical trialsContinue reading
Author Archive: Roxan Olivas
C-Path’s CPA-1 Consortium Welcomes Newest Members Kamada, Sanofi
TUCSON, Ariz., February 18, 2024 — Critical Path Institute’s® (C-Path)Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada and Sanofi, as its newest members. Continue reading
C-Path Announces Jennifer Kendra as New Vice President of Strategic Relationships
New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-PathContinue reading
C-Path’s TRxA Announces 2025 Request for Proposals from Academic Investigators
New Funding Opportunity for Drug Development ProjectsContinue reading
C-Path’s TRxA Announces $1 Million Award for Drug Development Project in Type 1 Diabetes
TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients. Continue reading
C-Path Announces Gender Equitable Medicines for Parkinson’s Disease (GEM‑PD) Initiative
C-Path expands its worldwide leadership in accelerating drug development in neurology; seeks additional collaborators to broaden impact.Continue reading
C-Path Announces Key Leadership Appointments in Neurodegenerative Disease Research
Dr. Diane Stephenson Promoted to Vice President of Neurology; Dr. Nadine Tatton Welcomed as New Executive Director of CPADContinue reading
C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies
TUCSON, Ariz., September 30, 2024 — Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.Continue reading
C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development
WASHINGTON, Sept. 12, 2024 — Critical Path Institute (C-Path) successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024, at the Washington Marriott at Metro Center in Washington, D.C. This landmark event brought together industry leaders, regulatory agencies, academic experts, and patient advocacy groups, all dedicated to advancing drug development and regulatory science for rare diseases. Continue reading